143 related articles for article (PubMed ID: 18673288)
1. Antibody-onconase conjugates: cytotoxicity and intracellular routing.
Rybak SM
Curr Pharm Biotechnol; 2008 Jun; 9(3):226-30. PubMed ID: 18673288
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD22 Onconase: preparation and characterization.
Newton DL; Stockwin LH; Rybak SM
Methods Mol Biol; 2009; 525():425-43, xiv. PubMed ID: 19252847
[TBL] [Abstract][Full Text] [Related]
3. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
Weber T; Mavratzas A; Kiesgen S; Haase S; Bötticher B; Exner E; Mier W; Grosse-Hovest L; Jäger D; Arndt MA; Krauss J
J Immunol Res; 2015; 2015():561814. PubMed ID: 26605343
[TBL] [Abstract][Full Text] [Related]
4. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
Newton DL; Hansen HJ; Mikulski SM; Goldenberg DM; Rybak SM
Blood; 2001 Jan; 97(2):528-35. PubMed ID: 11154233
[TBL] [Abstract][Full Text] [Related]
5. Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.
Krauss J; Arndt MA; Dübel S; Rybak SM
Curr Pharm Biotechnol; 2008 Jun; 9(3):231-4. PubMed ID: 18673289
[TBL] [Abstract][Full Text] [Related]
6. [Onconase: a ribonuclease with antitumor activity].
Zwolińska M; Smolewski P
Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleases as potential modalities in anticancer therapy.
Ardelt W; Ardelt B; Darzynkiewicz Z
Eur J Pharmacol; 2009 Dec; 625(1-3):181-9. PubMed ID: 19825371
[TBL] [Abstract][Full Text] [Related]
8. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
Ardelt W; Shogen K; Darzynkiewicz Z
Curr Pharm Biotechnol; 2008 Jun; 9(3):215-25. PubMed ID: 18673287
[TBL] [Abstract][Full Text] [Related]
9. Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.
Goparaju CM; Blasberg JD; Volinia S; Palatini J; Ivanov S; Donington JS; Croce C; Carbone M; Yang H; Pass HI
Oncogene; 2011 Jun; 30(24):2767-77. PubMed ID: 21317924
[TBL] [Abstract][Full Text] [Related]
10. Ribonucleases and immunoRNases as anticancer drugs.
Rybak SM; Arndt MA; Schirrmann T; Dübel S; Krauss J
Curr Pharm Des; 2009; 15(23):2665-75. PubMed ID: 19689337
[TBL] [Abstract][Full Text] [Related]
11. Intracellular pathway of Onconase that enables its delivery to the cytosol.
Rodríguez M; Torrent G; Bosch M; Rayne F; Dubremetz JF; Ribó M; Benito A; Vilanova M; Beaumelle B
J Cell Sci; 2007 Apr; 120(Pt 8):1405-11. PubMed ID: 17374640
[TBL] [Abstract][Full Text] [Related]
12. Sustained and cancer cell targeted cytosolic delivery of Onconase results in potent antitumor effects.
Zhao HL; Xue C; Du JL; Ren M; Xia S; Cheng YG; Liu ZM
J Control Release; 2012 May; 159(3):346-52. PubMed ID: 22715504
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapeutic RNases (ImmunoRNases).
Schirrmann T; Krauss J; Arndt MA; Rybak SM; Dübel S
Expert Opin Biol Ther; 2009 Jan; 9(1):79-95. PubMed ID: 19063695
[TBL] [Abstract][Full Text] [Related]
14. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.
Altomare DA; Rybak SM; Pei J; Maizel JV; Cheung M; Testa JR; Shogen K
BMC Cancer; 2010 Feb; 10():34. PubMed ID: 20137089
[TBL] [Abstract][Full Text] [Related]
15. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL
J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029
[TBL] [Abstract][Full Text] [Related]
17. Cancer chemotherapy--ribonucleases to the rescue.
Leland PA; Raines RT
Chem Biol; 2001 May; 8(5):405-13. PubMed ID: 11358688
[TBL] [Abstract][Full Text] [Related]
18. Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.
Vert A; Castro J; Ribó M; Benito A; Vilanova M
Oncotarget; 2017 Feb; 8(7):11692-11707. PubMed ID: 28035074
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
20. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
